{"id":"cisplatin-i-p","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nephrotoxicity"},{"rate":"10-30","effect":"Ototoxicity"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"25-30","effect":"Myelosuppression"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"15-25","effect":"Electrolyte abnormalities (hypomagnesemia, hypokalemia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which distort the DNA helix and block replication and transcription machinery. This leads to apoptosis in rapidly dividing cancer cells. The drug is non-cell-cycle specific and has been a cornerstone of cancer chemotherapy for decades.","oneSentence":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:03.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer (intraperitoneal administration)"},{"name":"Colorectal cancer (intraperitoneal administration)"},{"name":"Gastric cancer (intraperitoneal administration)"}]},"trialDetails":[{"nctId":"NCT04885270","phase":"PHASE3","title":"Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer","status":"UNKNOWN","sponsor":"West China Second University Hospital","startDate":"2021-08-04","conditions":"Epithelial Carcinoma, Ovarian, Neoadjuvant Chemotherapy","enrollment":50},{"nctId":"NCT00702299","phase":"PHASE1","title":"Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2007-09","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer","enrollment":15},{"nctId":"NCT00001332","phase":"PHASE1","title":"Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1992-12","conditions":"Peritoneal Neoplasms, Stomach Neoplasms","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["intraperitoneal cisplatin"],"phase":"phase_3","status":"active","brandName":"cisplatin i.p.","genericName":"cisplatin i.p.","companyName":"West China Second University Hospital","companyId":"west-china-second-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells. Used for Ovarian cancer (intraperitoneal administration), Colorectal cancer (intraperitoneal administration), Gastric cancer (intraperitoneal administration).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}